Our London-based capital markets lawyers advise major issuers and underwriters throughout Europe on global offerings of equity and securities. We also develop innovative securities that allow European financial institutions to meet regulatory capital requirements efficiently and advise these clients on cross-border payment, settlement and risk-management issues.

Our London office has also been involved in some of the largest European M&A transactions in recent years. Our M&A lawyers advise large and small corporations, investment banks and private equity funds on investments.

The London office is an integral part of the firm's global technology practice. We advise European technology companies in cross-border capital markets, mergers and acquisitions and private equity transactions. Our global corporate finance experience has allowed us to creatively and successfully adapt U.S.-developed financing techniques to the needs of European technology companies

• Rio Tinto ($3.9 billion). We advised the joint bookrunners on a $2 billion offering of notes by Rio Tinto Finance (USA) guaranteed by Rio Tinto plc and Rio Tinto Limited. We also advised dealer managers in connection with a concurrent $1.9 billion cash tender offer by Rio Tinto Finance (USA) Limited for any and all of its outstanding 5.875% notes due 2013. Rio Tinto Group is a global leader in finding, mining and processing the earth’s mineral resources.
• ING Bank ($3.25 billion). We advised the managers on a Rule 144A/Regulation S offering of notes by ING Bank, a part of ING Groep.
• Resolution Limited (£2 billion/US$3.2 billion). We advised Resolution Limited, a Guernsey-incorporated company set up to acquire and consolidate life assurance, asset management, general insurance, banking and diversified general financial companies in the United Kingdom and Western Europe, on its rights offering of ordinary shares. The proceeds were used to partially finance Resolution’s acquisition of the AXA UK Life Insurance Business.
• AEGON ($2.6 billion). We advised the underwriters on a two SEC-registered equity offering by AEGON, a Dutch insurance group.
• DnB NOR (NOK 14 billion/$2.5 billion). We advised the joint global coordinators and joint bookrunners on an underwritten rights offering of new shares of DnB NOR. The offering included a public offering in Norway and private placements to institutional investors outside Norway. Based in Oslo, DnB NOR is Norway’s largest financial services group.
• TDC A/S (DKK12.3 billion/$2.2 billion). We advised the joint global coordinators and joint bookrunners in connection with an offering by majority shareholders of ordinary shares in TDC A/S, Denmark’s leading provider of telecommunications and pay TV. This transaction was the second-largest public offering in Western Europe and the fourth-largest public offering in Europe in 2010.
• PANDORA ($2.1 billion). We advised PANDORA, a Danish designer, manufacturer, marketer and seller of jewelry, both domestically and abroad, in connection with its Rule 144A/Regulation S initial public offering of shares and listing on the Nasdaq OMX Copenhagen exchange. This was the largest Danish IPO since 1994 and the second-largest IPO in Western Europe in 2010.
• Reliance Holdings ($1.5 billion). We advised Reliance Holdings USA, a company focused on developing a business relating to the production of natural gas and liquids from various shale deposits in the United States, in connection with its Rule 144A/Regulation S offering of senior notes. The notes are guaranteed by our client Reliance Industries, an integrated energy company based in India.
• NXP Semiconductor ($1.5 billion). We advised the underwriters in connection with the $476 million SEC-registered initial public offering of NXP Semiconductors N.V. and we also advised the underwriters on the subsequent $1 billion SEC-registered secondary offering of common stock of NXP Semiconductors, a Dutch provider of application-specific semiconductors, in particular high-performance mixed-signal solutions.
• Taylor Wimpey/TMM Holdings ($955 million). We are advising Taylor Wimpey, a U.K.-based homebuilder, in connection with the $955 million sale of its U.S. and Canadian business to TMM Holdings, a partnership controlled by certain investment funds affiliated with TPG Capital, certain investment funds affiliated with Oaktree Capital Management and JH Investments.
• Novo Nordisk/ZymoGenetics ($885 million). We advised Novo Nordisk as a selling shareholder in connection with the approximately $885 million acquisition of ZymoGenetics, a Seattle, Washington-based biopharmaceutical company, by Bristol-Meyers Squibb. We also advised Novo Nordisk on its acquisition of 26,000,000 shares of common stock of Aradigm, a global producer of drug inhalation products.